Compare HURA & IPEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HURA | IPEX |
|---|---|---|
| Founded | 2009 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 123.2M |
| IPO Year | N/A | 2025 |
| Metric | HURA | IPEX |
|---|---|---|
| Price | $0.45 | $10.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 14.6K |
| Earning Date | 03-31-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $9.86 |
| 52 Week High | $5.03 | $10.40 |
| Indicator | HURA | IPEX |
|---|---|---|
| Relative Strength Index (RSI) | 17.62 | 59.39 |
| Support Level | $0.41 | $10.27 |
| Resistance Level | $0.75 | $10.35 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 12.57 | 87.50 |
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Inflection Point Acquisition Corp V is a blank check company.